To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer
Subjects voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance;
Age between 18 and 75 years (calculated based on the date of signing the informed consent form);
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Expected survival greater than 12 weeks;
History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)].
Diseases affecting intravenous injection or blood sampling.
Adverse reactions from prior therapies not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≤1, except for: grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant asymptomatic grade 2 laboratory abnormalities, hypothyroidism stabilized with hormone replacement, or other toxicities judged by investigator as non-safety risks.
Major surgery (Grade 3 or above per National Surgical Classification Catalog 2022), significant traumatic injury within 4 weeks prior to first dose, planned major surgery during study (except protocol-specified procedures), or presence of unhealed wounds/fractures.